Eli Lilly has signed a research and licensing agreement with Insilico Medicine worth up to $2.75 billion, one of the largest deals yet placing a major pharmaceutical company's money directly behind artificial intelligence-designed drugs.
Insilico Medicine, a Hong Kong-based AI drug developer, will receive $115 million upfront, according to Endpoints News. The remainder of the headline figure is tied to milestone payments as drug candidates advance through development and eventually reach the market.
According to CNBC, the agreement is aimed at bringing AI-developed drugs to the global market. Pharmaceutical Executive described the structure as a combined research and licensing pact designed to advance AI drug discovery broadly.
The deal is not Lilly's first contact with Insilico. According to Fierce Biotech, Lilly is "further embracing" Insilico's technology, suggesting an existing working relationship that this agreement significantly expands. A separate headline from Fierce Biotech also references a "$100M-plus research pact" as part of the broader arrangement.
Insilico uses AI to identify disease targets and design drug molecules, compressing steps that traditionally take years into months. The company is among a cohort of startups — alongside Recursion, Exscientia, and others — attempting to prove that machine learning can make pharmaceutical R&D faster and cheaper.
For Lilly, coming off blockbuster success with its GLP-1 drugs, the bet signals that even flush, pipeline-rich companies see AI as a structural shift in how medicines get made — not just a productivity tool but a potential source of entirely new therapies.